PEP-Therapy Alternatives & Competitors
12 companies similar to PEP-Therapy — Innovative peptides as targeted therapies for oncology
Companies similar to PEP-Therapy
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Australia
Cybrexa Therapeutics
Changing the paradigm for cancer treatment through the development of antigen-independent...
New Haven, United States
Orum Therapeutics
A public biotechnology company pioneering a novel class of protein degraders.
Lexington, United States
Track all PEP-Therapy competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Pacylex Pharmaceuticals, Inc.
A new target in cancer care - triggering selective lethality with a new class of drugs.
Edmonton, Canada
ProfoundBio
An oncology biotherapeutics company
Woodinville, United State...
Lisata Therapeutics, Inc.
Targeted Therapy Delivered
United States
January Therapeutics
Transformational Oncology
San Diego, United States
Kinnate Biopharma Inc.
Inspiring Hope to Those Battling Cancer
San Diego, United States
Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack...
San Diego, United States
ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, a...
Epsilogen Ltd
Harnessing the power of IgE
United Kingdom
About PEP-Therapy
PEP-Therapy is a clinical-stage biotechnology company founded in 2014 with a focus on developing innovative peptides as targeted therapies for oncology. Their first drug candidate, PEP-010, has shown promise as a pro-apoptotic agent with demonstrated anti-tumor efficacy in pre-clinical models and a favorable safety pro...
Development and commercialization of peptide therapies for targeted oncology treatment
Patients with various types of cancer, oncologists, pharmaceutical companies, research institutions
Oncology, Clinical-stage, Targeted Therapies, Peptide-based Drugs, Cancer Research, Cell-penetrating Peptides, Pro-apoptotic Agents, Intracellular Delivery, Protein-protein Interactions, Phase Ia/b Clinical Trial, Metastatic Solid Tumors, Drug Development, Research Collaboration, International Investment
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches PEP-Therapy and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at PEP-Therapy on 11 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 10 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
